New Global Guidelines Warn Against Obesity Drugs for Young Children

New global health guidelines have been released, warning against the use of weight-loss drugs for children under the age of ten. According to BBC Health, these new recommendations suggest that children in this age group should not be given obesity medications or GLP-1 injections, such as Mounjaro and Wegovy. These drugs are designed to help people lose weight, but health experts are concerned about using them on very young children.

While many of these medications are already approved for use in older adolescents, some doctors have been prescribing them 'off-label'—meaning they are used for purposes or age groups not officially approved by regulators. Furthermore, some drug companies are currently testing these treatments in children as young as six. The new guidelines aim to provide a clear direction for doctors and families who are facing the difficult challenge of managing childhood obesity.

BBC Health reports that the focus for children under ten should remain on healthy eating and regular physical activity rather than medicine or surgery. While the guidelines do not oppose scientific drug trials, they emphasize that lifestyle changes are the safest starting point. The report also notes that certain types of digital technology, such as activity trackers or online games that encourage movement, might be helpful tools for children, although the current evidence for these tools is still limited.

This update comes at a time when childhood obesity is becoming a major global concern. Estimates suggest that 170 million children and adolescents around the world are now considered obese. The situation is particularly worrying for the five-to-nine age group, where the number of obese children has quadrupled since 1990, rising from 2% to 8%. Additionally, by 2024, there were 35 million children under the age of five who were classified as overweight. Obesity in childhood is a serious issue because it increases the risk of developing various health problems, including type 2 diabetes, later in life.

Dr. Luz De Rigil, the Director of Nutrition and Food Safety at the organization behind these guidelines, stated that they strongly recommend against using obesity medicines, weight-management devices, or bariatric surgery—a type of surgery on the stomach or intestines to help a person lose weight—for children under ten. She explained that these treatments might be appropriate for older children and teenagers, but only after lifestyle changes have failed and if the young person is both mentally and physically prepared for the process.

Experts are also concerned about the long-term implications of starting these treatments at such a young age. Laurence Grummer-Strawn, the head of Nutrition and Food Safety Actions, raised important questions about how long a child would need to stay on these medications. He noted that there is currently no clear evidence to show that these drugs can be used as a temporary solution before switching to a healthy diet later in life. Because of this lack of information, the organization is being very careful about supporting these treatments without more solid proof of their safety and effectiveness.

This new guidance is part of an ongoing effort to understand and address health trends in younger populations. As the field of obesity treatment continues to change, health officials have promised to keep evaluating new evidence as it becomes available. For now, the message to parents and doctors is clear: prioritize healthy habits and proceed with extreme caution when considering medical interventions for the youngest patients. The goal is to ensure that children grow up in a way that supports their long-term health and well-being without relying on treatments that are not yet fully understood for their age group.